DFTX
Definium Therapeutics, Inc. · Healthcare · Biotechnology
All ownership figures: tracked 13F managers only, common-stock positions, reporting period Q4 2025
| # | Manager | Shares | Δ shares | Value | Their weight | Held | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Marshall Wace ✦ | 2.98M | New | $39.84M | 0.0% | New | 1 | SEC ↗ ×3 |
| 2 | Ensign Peak Advisors, Inc | 262.00K | — | $3.51M | 0.0% | n/c | 1 | SEC ↗ |
| 3 | T. Rowe Price ✦ | 52.23K | New | $700,000 | 0.0% | New | 1 | SEC ↗ |
“Their weight” = the position's share of that manager's reported 13F equity value — the conviction measure. ✦ = curated manager.
New buyers
| Marshall Wace | $39.84M | 0.0% |
| T. Rowe Price | $700,000 | 0.0% |
Exited
| No tracked exits this quarter. |
Full-market context: across ALL 13F filers (SEC structured data, Q1 2026): 244 holders, 74.15M shares, $1.40B reported. This is a different, older period than the tracked-universe figures above and the two are never mixed.
What else this security's tracked holders most often hold — shared-ownership counts, not fundamental relationships.
Open-market purchases (P)
No open-market insider purchases in our coverage window.
Open-market sales (S)
Officer · 14.05K sh · $513,845
Officer · 3.10K sh · $113,257
Officer · 3.38K sh · $123,497
Officer, Director · 31.55K sh · $1.15M
Officer, Director · 10.85K sh · $396,894
Officer, Director · 19.02K sh · $721,733
Awards, exercises and tax withholding are never counted as buys or sales here. Methodology